Opus Genetics, Stock Performance
| IRD Stock | 1.10 0.09 8.91% |
The company holds a Beta of 2.28, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Opus Genetics, will likely underperform. At this point, Opus Genetics, has a negative expected return of -0.0526%. Please make sure to check Opus Genetics,'s kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Opus Genetics, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Opus Genetics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Opus Genetics, is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
1 | Insider Trading | 10/22/2024 |
2 | Shareholder Alert Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders | 10/23/2024 |
3 | The RD Fund Announces Ocuphire Pharmas Acquisition of Opus Genetics - StockTitan | 10/25/2024 |
4 | Disposition of 37050 shares by Magrath George of Opus Genetics, at 1.18 subject to Rule 16b-3 | 11/01/2024 |
5 | Acquisition by Yerxa Benjamin R of 332800 shares of Opus Genetics, subject to Rule 16b-3 | 11/07/2024 |
6 | Acquisition by Magrath George of 90294 shares of Opus Genetics, at 1.0102 subject to Rule 16b-3 | 11/15/2024 |
7 | Acquisition by Magrath George of 9706 shares of Opus Genetics, at 1.0244 subject to Rule 16b-3 | 11/18/2024 |
8 | Opus Genetics Inc CEO George Magrath Purchases 100,000 Shares | 11/20/2024 |
9 | Acquisition by Yerxa Benjamin R of 10000 shares of Opus Genetics, at 0.9834 subject to Rule 16b-3 | 11/21/2024 |
10 | Opus Genetics president Benjamin Yerxa acquires 9,834 in stock | 11/25/2024 |
| Begin Period Cash Flow | 42.6 M |
Opus |
Opus Genetics, Relative Risk vs. Return Landscape
If you would invest 122.00 in Opus Genetics, on August 28, 2024 and sell it today you would lose (12.00) from holding Opus Genetics, or give up 9.84% of portfolio value over 90 days. Opus Genetics, is generating negative expected returns assuming volatility of 4.7146% on return distribution over 90 days investment horizon. In other words, 41% of stocks are less volatile than Opus, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Opus Genetics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Opus Genetics,, and traders can use it to determine the average amount a Opus Genetics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0111
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IRD |
Estimated Market Risk
| 4.71 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Opus Genetics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Opus Genetics, by adding Opus Genetics, to a well-diversified portfolio.
Opus Genetics, Fundamentals Growth
Opus Stock prices reflect investors' perceptions of the future prospects and financial health of Opus Genetics,, and Opus Genetics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Opus Stock performance.
| Revenue | 19.05 M | ||||
| Net Income | (9.99 M) | ||||
| Total Debt | 4.04 M | ||||
| Cash Flow From Operations | (1.11 M) | ||||
| Total Asset | 53.95 M | ||||
| Retained Earnings | (81.47 M) | ||||
About Opus Genetics, Performance
By analyzing Opus Genetics,'s fundamental ratios, stakeholders can gain valuable insights into Opus Genetics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Opus Genetics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Opus Genetics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Opus Genetics, is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about Opus Genetics, performance evaluation
Checking the ongoing alerts about Opus Genetics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Opus Genetics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Opus Genetics, generated a negative expected return over the last 90 days | |
| Opus Genetics, may become a speculative penny stock | |
| Opus Genetics, has high historical volatility and very poor performance | |
| Opus Genetics, has high likelihood to experience some financial distress in the next 2 years | |
| Opus Genetics, was previously known as Ocuphire Pharma and was traded on NASDAQ Exchange under the symbol OCUP. | |
| The company reported the last year's revenue of 19.05 M. Reported Net Loss for the year was (9.99 M) with profit before taxes, overhead, and interest of 0. | |
| Opus Genetics, generates negative cash flow from operations | |
| Opus Genetics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Opus Genetics president Benjamin Yerxa acquires 9,834 in stock |
- Analyzing Opus Genetics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Opus Genetics,'s stock is overvalued or undervalued compared to its peers.
- Examining Opus Genetics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Opus Genetics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Opus Genetics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Opus Genetics,'s stock. These opinions can provide insight into Opus Genetics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Opus Stock analysis
When running Opus Genetics,'s price analysis, check to measure Opus Genetics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics, is operating at the current time. Most of Opus Genetics,'s value examination focuses on studying past and present price action to predict the probability of Opus Genetics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics,'s price. Additionally, you may evaluate how the addition of Opus Genetics, to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |